<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Research in 2022 | ARSACS</title>
	<atom:link href="https://arsacs.com/fr/category/research-2022/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com/fr</link>
	<description>Research That Heals</description>
	<lastBuildDate>Mon, 16 Mar 2026 22:14:46 +0000</lastBuildDate>
	<language>fr-CA</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>Research in 2022 | ARSACS</title>
	<link>https://arsacs.com/fr</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The Krogan Lab team continues working on  ARSACS</title>
		<link>https://arsacs.com/fr/the-krogan-lab-team-continues-working-on-arsacs-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sun, 04 Dec 2022 23:29:05 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17985</guid>

					<description><![CDATA[The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they &#160;identified. “Our affinity purification mass spectrometry studies on sacsin have revealed a protein-proteininteraction with DAPK (Death-associated protein kinase)1/3, a positive mediator of gammainterferoninduced programmed cell death. Additionally, our analysis of the phosphorylationlandscape of WT and SACS-/- cell [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">The Krogan Lab researchers are currently performing mechanistic follow-up studies on a subset of the protein-protein interactions they &nbsp;identified.  </p>



<p class="wp-block-paragraph">“Our affinity purification mass spectrometry studies on sacsin have revealed a protein-protein<br>interaction with DAPK (Death-associated protein kinase)1/3, a positive mediator of gammainterferon<br>induced programmed cell death. Additionally, our analysis of the phosphorylation<br>landscape of WT and SACS-/- cell lines followed by bioinformatics analysis revealed that tau, a<br>known DAPK1 substrate, is differentially phosphorylated. To understand the role of sacsin in<br>DAPK1-mediated tau phosphorylation, we are currently overexpressing or inhibiting DAPK1. In<br>addition, to identify which region of the multi-domain protein sacsin is required to regulate tau<br>phosphorylation, we are expressing individual domains separately followed by analysis of tau<br>phosphorylation”.<br></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Elucidating mechanisms underlying motor coordination rescue in a mouse model of ARSACS&#8221; &#8211; Drs. Alanna Watt &#038; Anne McKinney</title>
		<link>https://arsacs.com/fr/elucidating-mechanisms-underlying-motor-coordination-rescue-in-a-mouse-model-of-arsacs-drs-alanna-watt-anne-mckinney-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 20:30:02 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17720</guid>

					<description><![CDATA[One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death are observed in both human patients and mouse models of ARSACs. Our work focuses [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>One of the hallmark features of ARSACS is dysfunction and eventual death of Purkinje cells in the cerebellum, which contributes to ataxia. Strikingly, not all Purkinje cells become ill and die: rather, specific patterns of vulnerability and resilience to cell death are observed in both human patients and mouse models of ARSACs. Our work focuses on identification of the factors that promote resilience or prevent vulnerability to cell death. For example, we recently reported that both the location and molecular profile of Purkinje cells are involved in determining cell survival or death (Toscano-Marquez et al., 2021). We continue this line of research with a focus on three hypotheses: (1) Can improving mitochondria function prevent cell death and reduce ataxia progression? (2) Does a pH regulator act as a therapeutic agent for ARSACs treatment? (3) Do changes in non-neuronal cells impact cerebellar function in ARSACS? Finally, we continue to explore novel pathways that could be targeted for future therapeutics.</p>
<p>Grant: $191,000 </p>
<p style="text-align: left;">Duration: second year of a 2 year project</p>
<p>Contact :<br /><img loading="lazy" decoding="async" class="wp-image-132 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/watt-1-150x150-2.jpg" alt="Dre Alanna Watt" width="198" height="198" /></p>
</p>
<p style="text-align: center;">Dr. Alanna Watt, <span style="font-size: 10.5pt; font-family: 'Open Sans',sans-serif; color: #666666;">Department of Biology</span></p>
<p style="text-align: center;">McGill University, Bellini Life Science  Building, room 265<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1 <br /><a href="mailto:alanna.watt@mcgill.ca"> alanna.watt@mcgill.ca</a></p>
</p>
<p style="text-align: center;">
<p style="text-align: center;"><img loading="lazy" decoding="async" class="wp-image-11142 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Anne-McKinney-150x150-2.jpg" alt="" width="201" height="201" /></p>
<p style="text-align: center;">Dr. Anne McKinney, Department of Pharmacology and Therapeutics </p>
<p style="text-align: center;">McGill University Bellini Life Science Building, room 167<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1<br /><a href="mailto:anne.mckinney@mcgill.ca"> anne.mckinney@mcgill.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS):  A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood”  &#8211; Drs. Justin Wolter, Matthis Synofzik &#038; David Mengel</title>
		<link>https://arsacs.com/fr/charting-the-neurodevelopmental-stage-of-arsacs-neurodevarsacs-a-cross-species-longitudinal-characterization-of-the-early-molecular-changes-in-the-brain-csf-and-blood-dr/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 20:18:36 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17722</guid>

					<description><![CDATA[It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early molecular and cellular changes that precede the loss of neurons in ARSACS, let alone biomarkers which would allow [...]]]></description>
										<content:encoded><![CDATA[<p>It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early molecular and cellular changes that precede the loss of neurons in ARSACS, let alone biomarkers which would allow us to track the earliest stages of the disease. Understanding the early changes in ARSACS will clarify fundamental molecular deficiencies, and motivate preemptive therapeutic strategies aimed at delaying, or possibly preventing, the progression of this disease.</p>
<p>The goals of this project are to generate a cross-species map of the developmental trajectory of ARSACS through the lens of molecular and cellular deficits in the ARSACS mouse model, and readily accessible fluid biomarkers in mice and human patients. This paired longitudinal study design will allow us to mechanistically anchor readily available fluid biomarkers with early cellular abnormalities in the ARSACS brain.</p>
<p>Subvention : $100 000</p>
<p style="text-align: left;">Duration:  2nd year of a 2 year project</p>
<p>Contact : </p>
<p style="padding-left: 40px; text-align: left;"><img loading="lazy" decoding="async" class="wp-image-11785 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Matthis_Synofzik.jpg" alt="" width="198" height="198" /></p>
<p style="padding-left: 40px; text-align: left;">Dr. Matthis Synofzik </p>
<p style="text-align: left; padding-left: 40px;"> Hertie- Institute for Clinical Brain Research<br /> Hoppe-Seyler-Strasse 3, 72076 Tubingen, Germany <br /><a href="mailto:matthis.synofzik@uni-tuebingen.de"> matthis.synofzik@uni-tuebingen.de</a></p>
<p style="padding-left: 40px; text-align: left;"><img loading="lazy" decoding="async" class="wp-image-16104 alignleft" src="https://arsacs.com/wp-content/uploads/2021/12/David_Mengel-HF-cropped-1-225x300.jpg" alt="" width="198" height="263" /></p>
<p style="padding-left: 200px;">Dr. David Mengel </p>
<p style="padding-left: 200px;"> Hertie- Institute for Clinical Brain Research<br /> Hoppe-Seyler-Strasse 3, 72076 Tubingen, Germany <br /> <a class="rABsFf RffVmb AL18ce" href="mailto:david.mengel@uni-tuebingen.de" target="_blank" rel="noopener" data-tooltip-position="top" data-tooltip="From your Google Contacts">david.mengel@uni-tuebingen.de</a></p>
<p style="padding-left: 240px;"> </p>
<p style="text-align: left; padding-left: 40px;"><img loading="lazy" decoding="async" class="wp-image-11490 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Justin-Wolter1-e1604075278293.jpg" alt="" width="174" height="261" /></p>
<p style="text-align: left; padding-left: 200px;"><span style="font-size: revert;">Dr Justin Wolter </span></p>
<p style="text-align: left; padding-left: 200px;">Mary Ellen Jones Building CB#7250<br />116 Manning Dr., Chapel Hill, NC, US 27599<br /><a href="mailto:justin_wolter@med.unc.edu">justin_wolter@med.unc.edu</a></p>
<p style="text-align: center;"> </p>


<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Therapeutic Approaches for ARSACS&#8221;- Drs. Benoit Gentil and Heather Durham</title>
		<link>https://arsacs.com/fr/therapeutic-approaches-for-arsacs-drs-benoit-gentil-and-heather-durham-5/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 20:14:12 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17718</guid>

					<description><![CDATA[ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors and, because of the chaperone function of sacsin, we investigate the potential of [...]]]></description>
										<content:encoded><![CDATA[<p>ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies.<em> </em>Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors and, because of the chaperone function of sacsin, we investigate the potential of alternative therapies already in development in our laboratory to promote protein chaperoning. We have studied domains functions necessary for the replacement therapy and identified that HDAC inhibitors, or chaperone inducers have a strong therapeutic potential. Our laboratory is moving forward the development of a gene therapy and focused on the development of peptide and gene therapies. We have generated a vector for gene therapy and move forward our project to determine its efficiency. Our lab is also working on finding other therapeutic strategies and we are assessing the therapeutic potential of brain permeant HDAC inhibitors for ARSACS<strong>.</strong> We will examine the role of different HDACs inhibitors in resorbing intermediate filaments bundles and affecting Rab1 homeostasis which is affected in ARSACS. </p>
<p>Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contacts<br /><img loading="lazy" decoding="async" class="alignleft  wp-image-3643" src="https://arsacs.com/wp-content/uploads/2021/02/Durham_Benoit_Nov_2017-150x150-2.jpg" alt="" width="199" height="199" /></p>
<p>Le Dr Benoit Gentil  et le Dr Heather Durham</p>
<p><span style="font-size: revert;">Département de kinésiologie et d'éducation physique, Université McGill </span></p>
<p>475 Pine Avenue West,   room 210,  Montreal (Québec)  H2W 1S4</p>
<p> heather.durham@mcgill.ca, <span style="font-size: revert;"> benoit.gentil@mcgill.ca</span></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Unraveling the role of glial cells in ARSACS Rationale”  &#8211; Drs. Federico Herrera, Adelaide Fernandes &#038; Michelle Adams</title>
		<link>https://arsacs.com/fr/unraveling-the-role-of-glial-cells-in-arsacs-rationale-drs-federico-herrera-adelaide-fernandes-michelle-adams/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 19:35:51 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17735</guid>

					<description><![CDATA[Glial cells play key roles in developmental and neurodegenerative disorders, including some with remarkable similarities with ARSACS, such as Alexander disease and Giant Axonal Neuropathy. We and others have found high levels of sacsin expression in rodent and human astroglia and microglia. Sacsin deletion in rat astroglial-like cells disrupts glial intermediate filament networks (GFAP, Vimentin, [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>Glial cells play key roles in developmental and neurodegenerative disorders, including some with remarkable similarities with ARSACS, such as Alexander disease and Giant Axonal Neuropathy. We and others have found high levels of sacsin expression in rodent and human astroglia and microglia. Sacsin deletion in rat astroglial-like cells disrupts glial intermediate filament networks (GFAP, Vimentin, Nestin) and the response of these cells to oxidative stress and inflammatory cues. These results indicated that sacsin is relevant for glial biology and opened the possibility that alterations in glial cells could be involved in ARSACS. To address these issues, we will 1) develop new ARSACS astroglial and microglial human cell models and analyze their molecular and cellular alterations (Herrera Lab); and 2) analyze glial behavior and function during neuronal development and disease manifestation in mouse (Fernandes Lab) and zebrafish (Adams Lab) models of ARSACS. If we find relevant glial alterations during this descriptive approach, we intend to advance towards the design and preclinical testing of potential therapeutic interventions. Our results could lay the groundwork for formulating new therapeutic strategies targeting glia rather than neurons in ARSACS and similar pathologies.</p>
</p>
<p>Subvention : $100 000</p>
<p style="text-align: left;">Durée : un an</p>
<p>Contacts : </p>
<p style="padding-left: 40px; text-align: left;"><img loading="lazy" decoding="async" class="wp-image-17747 alignleft" src="https://arsacs.com/wp-content/uploads/2022/10/Federico_Herrera-300x300.jpeg" alt="" width="223" height="223" /></p>
<p style="padding-left: 40px; text-align: left;">
<p style="padding-left: 40px; text-align: left;">Dr. Federico Herrera, Dep. of Chemistry and Biochemistry (DQB)<br /> Faculty of Sciences, University of Lisbon<br /> Edifício C8, Campo Grande, 1749-016 Lisboa</p>
<p style="padding-left: 40px; text-align: left;"><a href="mailto:fherrera@fc.ul.pt">fherrera@fc.ul.pt</a></p>
</p>
<p style="padding-left: 40px;"><img loading="lazy" decoding="async" class="wp-image-17743 alignleft" src="https://arsacs.com/wp-content/uploads/2022/10/Adelaide-Fernandes-iMed-300x300.jpg" alt="" width="222" height="222" /></p>
</p>
<p style="padding-left: 40px;">Dr. Adelaide Fernandes</p>
<p style="padding-left: 40px; text-align: left;">Dep. of Pharmaceutical Sciences and Medicines Faculty of Pharmacy, University of Lisbon<br />Avenida, Professor Gama Pinto,1649-003 Lisboa</p>
<p style="padding-left: 40px; text-align: left;"><a href="mailto:amaf@ff.ulisboa.pt">amaf@ff.ulisboa.pt</a></p>
</p>
<p><img loading="lazy" decoding="async" class="wp-image-17765 alignleft" src="https://arsacs.com/wp-content/uploads/2022/10/Michelle_Adams_CROP-237x300.jpg" alt="" width="224" height="284" srcset="https://arsacs.com/wp-content/uploads/2022/10/Michelle_Adams_CROP-237x300.jpg 237w, https://arsacs.com/wp-content/uploads/2022/10/Michelle_Adams_CROP.jpg 435w" sizes="(max-width: 224px) 100vw, 224px" /></p>
</p>
<p>        Dr. Michelle Adams</p>
<p style="text-align: left;">         Psychology department, Bilkent University</p>
<p>         Ankara, TR 06800</p>
<p style="text-align: left;">       <a href="mailto:michelle@bilkent.edu.tr"> michelle@bilkent.edu.tr</a></p>
</p>
<p style="padding-left: 40px; text-align: left;"><span style="font-size: revert;"> </span></p>
</p>
<p style="padding-left: 40px;">
<p style="text-align: left; padding-left: 240px;">
<p style="text-align: left;">
<p style="text-align: center;">
<p style="text-align: center;">
<p style="text-align: center;">


<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Metabolic rewiring in cellular models of ARSACS”  &#8211; Dr.Paul Chapple</title>
		<link>https://arsacs.com/fr/metabolic-rewiring-in-cellular-models-of-arsacs-dr-paul-chapple-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 19:20:48 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17733</guid>

					<description><![CDATA[The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s. Recent technical advances in the analysis of cellular metabolites mean it is now possible to simultaneously quantify the passage of multiple [...]]]></description>
										<content:encoded><![CDATA[The viability of neurons in the brain depends on a complex series of interconnected biochemical reactions that constitute cellular metabolism. Disruption of these metabolic pathways is associated with neurological conditions, including Alzheimer’s and Parkinson’s. Recent technical advances in the analysis of cellular metabolites mean it is now possible to simultaneously quantify the passage of multiple metabolites through cells over time. We will leverage this metabolomic flux analyses to compare the metabolite profiles of control cells and cells that lack the protein sacsin, which is mutated in ARSACS. We believe disruption of cellular metabolism is likely to be particularly relevant to ARSACS. This is because it has previously been shown that the health of mitochondria, organelles where key metabolic enzymes are located, is reduced in cellular and animal models of ARSACS. Our goal is to define the metabolic changes that occur in sacsin deficient cells as we believe this will elucidate ARSACS disease mechanism and potentially identify targets for therapeutic intervention.

Grant: £37,714

Duration: first year of a 2 year project

Contact:
<p style="text-align: left;"><img loading="lazy" decoding="async" class="wp-image-17311  alignleft" src="https://arsacs.com/wp-content/uploads/2022/07/Paul_chapple_2022_-Research-report_website-150x150.jpg" alt="" width="165" height="165" /></p>
<p style="text-align: left;">Dr. Paul Chapple , Faculty of Medicine and Dentistry
Queen Mary University of London
London UL
<a href="mailto:j.p.chapple@qmul.ac.uk">j.p.chapple@qmul.ac.uk</a></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Identifying Clinically Relevant Compounds and Their Molecular Targets Modulating the Purkinje Neuronal Excitability in ARSACS  patients”   &#8211; Dr.Mohan Babu</title>
		<link>https://arsacs.com/fr/identifying-clinically-relevant-compounds-and-their-molecular-targets-modulating-the-purkinje-neuronal-excitability-in-arsacs-patients-dr-mohan-babu/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 19:12:51 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17725</guid>

					<description><![CDATA[Despite extensive research, the underlying causes of neurodegeneration in ARSACS still remain unclear, and thus there is a need for identifying effective therapies for ARSACS patients. My lab over the past several years has focused on characterizing the changes of macromolecular assemblies in ARSACS patients, as well as mapping the ARSACS-linked SACS pathways, to reveal [...]]]></description>
										<content:encoded><![CDATA[Despite extensive research, the underlying causes of neurodegeneration in ARSACS still remain unclear, and thus there is a need for identifying effective therapies for ARSACS patients. My lab over the past several years has focused on characterizing the changes of macromolecular assemblies in ARSACS patients, as well as mapping the ARSACS-linked <em>SACS </em>pathways, to reveal potential drivers of ARSACS. Aberrant alteration of neuronal excitability contributes to increased calcium influx in neurons, which can lead to neurological disorders, including ARSACS. Therefore, identifying molecular targets modulating excitability in human neurons carrying <em>SACS </em>gene mutation in ARSACS patients is a promising first step towards exploring therapeutic interventions. In this newly funded proposal, we will perform a phenotypic screen against annotated compounds in iPSC-derived human neurons carrying the <em>SACS</em> ARSACS mutation to identify molecular targets that restore cellular phenotypes of ARSACS, such as altered neuronal excitability, to the normal state. The role of promising excitability modulators will then be interrogated in ARSACS disease pathogenesis. Identification of drugs acting on targets that modulate abnormal excitability should lay the foundation for future drug development programs for ARSACS.

Grant: $100,000

Duration: one year

Contact:

<img loading="lazy" decoding="async" class="size-full wp-image-10781 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrMohanBabu.jpg" alt="" width="132" height="148" />

Dr. Mohan Babu, Department of Biochemistry University of Regina
3737 Wascana Parkway, Regina,  SK S4S 0A2
<a href="mailto:mohan.babu@uregina.ca">mohan.babu@uregina.ca</a>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Targeting transmembrane ion balance to restore Purkinje cell functionality in ARSACS” &#8211; Dr. Francesca Maltecca</title>
		<link>https://arsacs.com/fr/targeting-transmembrane-ion-balance-to-restore-purkinje-cell-functionality-in-arsacs-dr-francesca-maltecca-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 19:09:09 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17716</guid>

					<description><![CDATA[We identified in murine Purkinje cells a specific interaction of sacsin with proteins regulating transmembrane ion balance, which are required for tuning the firing properties of these neurons. Our functional studies support a deregulation of ion conductance in Sacs-/-  Purkinje cells compared to controls. By complementary approaches in vivo and ex vivo, the project aims [...]]]></description>
										<content:encoded><![CDATA[<p>We identified in murine Purkinje cells a specific interaction of sacsin with proteins regulating transmembrane ion balance, which are required for tuning the firing properties of these neurons. Our functional studies support a deregulation of ion conductance in <em>Sacs<sup>-/-</sup></em>  Purkinje cells compared to controls. By complementary approaches <em>in vivo</em> et <em>ex vivo</em>, the project aims at dissecting and targeting defects in this pathway, to understand their contribution to the ataxic phenotype observed in ARSACS. The final aim is the identification of new valuable targets for therapeutic intervention.</p>
<p class="PANormalLevelIA" style="text-align: justify;">Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p style="text-align: left;"><img loading="lazy" decoding="async" class="size-full wp-image-11103 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrFrancescaMaltecca-150x150-2.jpg" alt="" width="150" height="150" /></p>
<p>Dre Francesca Maltecca</p>
<p>Ospedale San Raffaele</p>
<p>Via Olgettina 58,20132, Milan, Italy  </p>
<p> <a href="mailto:maltecca.francesca@hsr.it">maltecca.francesca@hsr.it</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Détermination de la structure de la saccine ” – Dr Walid Houry</title>
		<link>https://arsacs.com/fr/structural-determination-of-sacsin-dr-walid-houry-5/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 19:01:19 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17713</guid>

					<description><![CDATA[Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a juvenile progressive movement disorder caused by mutations in a gene called SACS, which produces a protein with the same name (SACS or sacsin). The disease is characterized by very early onset, where the afflicted individual shows signs of neuropathy. Knowledge of the protein structure is crucial [...]]]></description>
										<content:encoded><![CDATA[<p>Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a juvenile progressive movement disorder caused by mutations in a gene called SACS, which produces a protein with the same name (SACS or sacsin). The disease is characterized by very early onset, where the afflicted individual shows signs of neuropathy. Knowledge of the protein structure is crucial for providing clues to its biological activity and to identify or design drugs that can bind to and correct the protein properties and function. Unfortunately, the sacsin protein is among the largest in human cells (4579 amino acid residues), which hindered determination of its structure and made basic biochemical experiments problematic. In the previous funding period, we made good progress towards tagging sacsin, purifying the full-length native protein, and obtaining initial electron microscopy (EM) images of the full-length protein. This is the first time that full length sacsin has been imaged. This was only possible by the previous funding support provided by The Ataxia Charlevoix-Saguenay Foundation. Here, through the continued support of the Foundation, we propose to scale up our protein purification efforts to obtain a high-resolution structure of sacsin using cryoEM.</p>
<p>Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignleft  wp-image-6572" src="https://arsacs.com/wp-content/uploads/2021/02/Walid_Houry_University_Toronto-e1606423339816.jpg" alt="" width="200" height="236" /></p>
<p>Dr. Walid A. Houry, Department of Biochemistry</p>
<p>Faculté de médecine Temerty de l'Université de Toronto<br />661 University Avenue,MaRS Centre, West Tower, Room 1612</p>
<p>Toronto, ON, Canada M5G 1M1</p>
<p> <a href="mailto:walid.houry@utoronto.ca">walid.houry@utoronto.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Retinal pigment epithelium (RPE) cell system to uncover the molecular mechanisms of ARSACS – related retinal effects” &#8211; Dr. Daniele Galatolo</title>
		<link>https://arsacs.com/fr/retinal-pigment-epithelium-rpe-cell-system-to-uncover-the-molecular-mechanisms-of-arsacs-related-retinal-effects-dr-daniele-galatolo-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Tue, 25 Oct 2022 18:55:33 +0000</pubDate>
				<category><![CDATA[Research in 2022]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=17711</guid>

					<description><![CDATA[Retinal and eye abnormalities are among the clinical hallmarks in ARSACS and have been described since first reports. Those defects have been confined to an unexplored field by a molecular point of view, compared to those related to brain and cerebellum that have been obvious targets for in vitro and in vivo studies so far. [...]]]></description>
										<content:encoded><![CDATA[Retinal and eye abnormalities are among the clinical hallmarks in ARSACS and have been described since first reports. Those defects have been confined to an unexplored field by a molecular point of view, compared to those related to brain and cerebellum that have been obvious targets for <em>in vitro</em> et <em>in vivo</em> studies so far. The goal of this study is to investigate the molecular mechanisms underlying retinal and eye abnormalities using retinal pigment epithelium (RPE) cells as model, and to identify potential targets for future pharmacological tests in more complex systems like ARSACS animal models. Objectives of this projects are:

i) To generate a knock-out model of ARPE-19 cells, a widely used RPE cell line.

ii) To characterize the knock-out phenotype assaying main molecular defects so far observed in other ARSACS models, and test principal RPE-related features.

iii) To perform a multi-omics analysis to understand the altered mechanisms that drive to retinal abnormalities and to identify druggable targets potentially able to ameliorate, halt, or slow down the progression of ocular phenotype.

Grant: $46,000

Duration : one yea

Contact:

<img loading="lazy" decoding="async" class="wp-image-15770 alignleft" src="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg" alt="" width="188" height="281" srcset="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg 201w, https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo.jpg 408w" sizes="(max-width: 188px) 100vw, 188px" />

Dr. Daniele Galatolo

Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit

IRCCS Stella Maris Foundation

via dei Giacinti 2,

56128 Calambrone (Pisa) - Italy

<a href="mailto:daniele.galatolo@fsm.unipi.it">daniele.galatolo@fsm.unipi.it</a>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>